Atara Biotherapeutics, Inc (ATRA) is a publicly traded Healthcare sector company. As of September 30, 2026, ATRA trades at $8.39 with a market cap of $84.02M and a P/E ratio of -6.35. ATRA moved +4.25% today. Year to date, ATRA is -55.50%; over the trailing twelve months it is -41.71%. Its 52-week range spans $3.92 to $19.15. Analyst consensus is buy with an average price target of $15.50. Rallies surfaces ATRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
2 analysts cover ATRA: 0 strong buy, 2 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $15.50.
| Metric | Value |
|---|---|
| Price | $8.39 |
| Market Cap | $84.02M |
| P/E Ratio | -6.35 |
| EPS | $-1.28 |
| Dividend Yield | 0.00% |
| 52-Week High | $19.15 |
| 52-Week Low | $3.92 |
| Volume | 192 |
| Avg Volume | 0 |
| Revenue (TTM) | $6.19M |
| Net Income | $-16.69M |
| Gross Margin | 0.00% |
2 analysts cover ATRA: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $15.50.